HeartFlow, Inc., Redwood City, Calif., announcesnew data which indicate that the information provided by the HeartFlow FFRct Analysis was a superior predictor of 10-year outcomes compared to the severity of a coronary stenosis shown on a coronary computed tomography angiogram (CTA). The 10-year results from the DISCOVER-FLOW trial were presented as a late-breaking trial during the virtual EuroPCR conference.

“When diagnosing and managing patients with coronary artery disease, physicians want to understand the impact of treatment. We want to be able to provide immediate symptom relief and have confidence that the treatment we are selecting, specifically the possible benefits of revascularization, will have a positive, long-lasting impact,” says Bon-Kwon Koo, MD, PhD, FACC, professor of internal medicine, Seoul National University, and director of the Cardiovascular Center and chair of the cardiology division, Seoul National University Hospital.

“The 10-year outcomes indicate that FFRct is a more useful non-invasive test than coronary CT alone as the information provided helps physicians with long-term risk stratification and treatment selection for patients with coronary artery disease,” Koo adds.

The DISCOVER-FLOW trial was the first-in-human trial evaluating the HeartFlow Analysis and enrolled 103 patients from four international hospitals. All patients received a HeartFlow Analysis following a coronary CT scan.

“It’s rare to have the opportunity to follow patients for 10 years in clinical trials and we were pleased to confirm the long-term prognostic value of FFRct through the DISCOVER-FLOW trial,” says Campbell Rogers, MD, FACC, chief medical officer, HeartFlow. “These new data are a reflection of the company’s commitment to providing comprehensive clinical evidence on the diagnostic accuracy, safety, efficacy, and utility of the HeartFlow Analysis to help clinicians engage patients in the decision-making process and confidently diagnose and optimize treatment for patients with coronary artery disease.”